Aller au contenu principal
Profil bibliographique

Mayur K. Ladumor

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

25Publications signalées
409Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Pharmacogenetics and Drug MetabolismDrug Transport and Resistance MechanismsAnalytical Methods in PharmaceuticalsLiver Disease Diagnosis and TreatmentAnalytical Chemistry and Chromatography

Les publications récentes

Accès ouvert 2026 article OpenAlex

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli et autres

ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless …

us, nl, de, it, kr, br, ca (code pays fourni par la source)

0 citations Clinical Pharmacology & Therapeutics
Accès ouvert 2023 article OpenAlex

Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model

Flavia Storelli, Mayur K. Ladumor, Xiaomin Liang, Yurong Lai et autres

Abstract Hepatic impairment (HI) moderately (<5‐fold) affects the systemic exposure (i.e., area under the plasma concentration–time curve [AUC]) of drugs that are substrates of the hepatic sinusoidal organic anion transporting polypeptide (OATP) transporters and are excreted unchanged in the bile and/or urine. …

us, be (code pays fourni par la source)

3 citations CPT Pharmacometrics & Systems Pharmacology
Accès ouvert 2022 article OpenAlex

Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes

Mayur K. Ladumor, Flavia Storelli, Xiaomin Liang, Yurong Lai et autres

Physiologically based pharmacokinetic models, populated with drug-metabolizing enzyme and transporter (DMET) abundance, can be used to predict the impact of hepatic impairment (HI) on the pharmacokinetics (PK) of drugs. To increase confidence in the predictive power of such models, they must be …

us, gb, be (code pays fourni par la source)

18 citations CPT Pharmacometrics & Systems Pharmacology
Accès ouvert 2022 article OpenAlex

The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans

Flavia Storelli, Mengyue Yin, Aditya R. Kumar, Mayur K. Ladumor et autres

This is the accepted manuscript version of the work published in its final form as Storelli, F., Yin, M., Kumar, A. R., Ladumor, M. K., Evers, R., Chothe, P. P., Enogieru, O. J., Liang, X., Lai, Y., & Unadkat, J. D. (2022). …

0 citations Zenodo (CERN European Organization for Nuclear Research)
Accès ouvert 2022 article OpenAlex

Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model

Jinfu Peng, Mayur K. Ladumor, Jashvant D. Unadkat

Pregnant women are frequently prescribed drugs to treat chronic diseases such as human immunodeficiency virus infection, but little is known about the benefits and risks of these drugs to the fetus that are driven by fetal drug exposure. The latter can be …

cn, us (code pays fourni par la source)

12 citations Drug Metabolism and Disposition

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.